Empowering Scientists for the Benefit of Human Health


The Leader in Cell Line Development

Selexis is the global leader in mammalian cell line development that leverages best-in-class protein expression technologies and modular workflows to create highly specialized solutions that enable the bio-pharmaceutical industry to streamline the drug discovery through development continuum and rapidly commercialize innovative biologic-based medicines and vaccines against diseases of high unmet need such as cancer, autoimmune and inflammatory diseases, infectious diseases, blood, metabolic and genetic disorders as well as dermatology and ophthalmic diseases.

Connect with us. From ubiquitous immunoglobulin-based drugs such as monoclonal and multispecific antibodies and Fc Fusions to novel scaffolds and difficult-to-express proteins, Selexis is your partner of choice.

Protein Expression with the SUREtechnology PLATFORM

Selexis Genetic Elements Technologies Icon

Advanced Gene Technologies

Selexis SGE® (Selexis Genetic Elements)

SUREtech Vectors™

SUREfection Procedures™

SUREvariant Screening™

Selexis CHO-M Cell Line Icon

Proprietary CHO-M Cell Line

CHO-M Cell Line™ (CHO-K1)

SURE CHO-Mplus Libraries™

Selexis Media and Feed Strategies-02

Media and Feed Strategies

SUREfeed Strategy™

Off-the-Shelf Media

Off-the-Shelf Feed

Selexis Clonality Icon

Product and Cell Line Analytics/ Characterization



Product Quality

News, Events and Blog

2 min read

KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer

KBI Biopharma, Inc. (KBI) and Selexis SA (Selexis) today announced that Abdelaziz Toumi, Ph.D., will begin serving as...

Read More

Bio Europe SPRING, Basel, Switzerland | March 28 – 31, 2022

Read More
4 min read

A Look Back at 2022

What a year 2022 turned out to be! It was a year of growth and expansion, with many exciting successes for Selexis as...

Read More

Bioprocessing 4.0


"In today’s biotechnology landscape, to be competitive, meet regulations, and achieve market demands, we must apply Bioprocessing 4.0,"

Selexis CHO cells high expressing mAB bispecific antibody



Our global partners are utilizing Selexis protein expression technologies and proprietary CHO cell line to advance a pipeline of more than 158 drug products in clinical development and the manufacture of 10 commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks.



Connect with Us